Aptiv vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dublin automotive technology (NYSE: APTV) ~$15B revenue; Gen 6 ADAS AI hands-free driving, 800V EV electrical architecture, software-defined vehicle platform for OTA updates competing with Lear and Mobileye.
About
Aptiv PLC is a Dublin, Ireland-headquartered (operational headquarters in Troy, Michigan) automotive technology company — publicly traded on the New York Stock Exchange (NYSE: APTV) as an S&P 500 Consumer Discretionary component — providing automotive high-voltage electrical architecture systems, advanced driver assistance systems (ADAS), software-defined vehicle platforms, and vehicle connectivity solutions to global automotive original equipment manufacturers through approximately 160,000 employees in 45 countries. Aptiv was spun off from Delphi Automotive in 2017 as the technology-focused entity (retaining signal and power distribution, ADAS, and connectivity businesses) while Delphi Technologies (powertrain components, subsequently acquired by BorgWarner) was separated. At CES 2025, Aptiv showcased its Gen 6 ADAS Platform — featuring AI/ML-powered hands-free driving capable of handling 95%+ of highway driving scenarios — alongside 360-degree perception systems combining bird's-eye-view cameras with ultrashort-range radar, and advanced power distribution architectures designed for software-defined vehicles and high-voltage electric vehicle platforms. CEO Kevin Clark leads Aptiv's strategy of expanding from traditional wiring harnesses and junction boxes toward software-defined vehicle architecture — the migration of automotive electronics from domain-specific ECUs (electronic control units) to centralized compute platforms where software can be updated over-the-air — a fundamental vehicle architecture change that positions Aptiv as the electrical nervous system supplier for next-generation vehicles.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.